According to a study, the global pharmaceutical market is expected to reach USD 3,148 billion by 2034. The projection anticipates the advancement of research and increased scope for innovative treatments to address demanding and rising healthcare needs. On the other side, global health authorities are tightening the Regulatory pathways to ensure that end-users get the right medicine for accurate diagnosis. In this scenario, to deal with a highly regulated industry – pharmaceuticals, manufacturers must understand the regional as well as global Regulatory landscape for accurate dossier preparation, quick healthy authority reviews, approvals, and registrations enabling on-time market entry.Â
At Vigilare, our priority lies in simplifying challenging regulatory pathways for pharmaceutical manufacturers. With cross-functional expertise and robust domain knowledge, we bring to the table 360-degree pharmaceutical regulatory consulting solutions that span across Pharmacovigilance, and Medical Writing. We aim to bring novel and innovative therapies to market with a strong emphasis on compliance.
Drug safety is not optional. It is critical for pharma manufacturers. We at Vigilare ensure that it is followed across the product life cycle. Right from Medical Literature monitoring and MICC activities to submissions of the ICSR cases to the regulatory authorities and from aggregate reporting to signal management, RMPs etc , our expert pharma regulatory consulting team focuses on managing global compliance
The scientific data is complex. Translating it in a compelling, and compliant way is our forte. Our pharma regulatory consulting team ensure your data is publishing-ready with utmost clarity and accuracy and adhering to Regulatory guidelines irrespective of the type of document you are working on, such as Clinical Study Reports (CSRs), clinical summaries, protocols, and safety narratives.
Aiming for smooth market entry without reliable Regulatory intelligence on regional compliance and Regulatory procedural standards is similar to walking the unknown and risking decades of efforts on pharmaceutical innovations. At Vigilare, we assist pharma manufacturers with informed decisions across the product life cycle and assist them with market-entry strategy, publ
publishing and submission procedures, product registrations, and post-approval life cycle maintenance.
Costs vary widely based on scope, geography, and project complexity. Project-based engagements for a single regulatory submission may range from $15,000 to $150,000+. Retainer-based models, common for ongoing regulatory affairs support, typically run $5,000 to $30,000 per month. FDA meeting preparation and representation services are often scoped separately. A fit-gap assessment is usually the first step to defining a tailored cost estimate.
Hiring a regulatory consultant is most valuable at critical decision points: pre-IND strategy, before a major agency interaction, during CMC scale-up, ahead of NDA/BLA filing, and when entering a new geographic market. Early-stage biotechs benefit from outsourced regulatory expertise to avoid costly missteps. Established companies often engage consultants for specific therapeutic areas, niche expertise, or to supplement internal capacity during peak workloads.
Regulatory affairs is an internal business function responsible for managing submissions, compliance, and agency relationships as an ongoing organizational role. Regulatory consulting is an external advisory service brought in for specific expertise, bandwidth, or strategic guidance. Many companies use both: permanent regulatory affairs staff for day-to-day work, supplemented by consultants for specialized submissions, audits, or market expansion.
Yes. Experienced regulatory consultants can act as authorized representatives or technical advisors in agency communications, Type A/B/C meeting requests, teleconferences, and written responses. For FDA submissions, a U.S. agent designation is required for foreign manufacturers. Consultants with former agency experience such as ex-FDA or ex-EMA reviewers provide particularly high-value representation due to institutional knowledge of internal review processes.